Therapeutic effect of oral dipyridamole on myocardial perfusion and cardiac performance in patients with hypertrophic cardiomyopathy
| Autor: | Toyofumi Wada, Ryutaro Yamaguchi, Hironori Toshima, Yoshinori Koga, Kazuo Kihara |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Male
Cardiac function curve medicine.medical_specialty Heart disease Cardiomyopathy Administration Oral Scintigraphy Coronary Circulation Internal medicine medicine Humans cardiovascular diseases Radionuclide Imaging medicine.diagnostic_test business.industry Therapeutic effect Hypertrophic cardiomyopathy Heart Dipyridamole Cardiomyopathy Hypertrophic Middle Aged medicine.disease Thallium Radioisotopes Exercise Test cardiovascular system Cardiology Female Cardiology and Cardiovascular Medicine business Perfusion medicine.drug |
| Zdroj: | American Heart Journal. 123:433-438 |
| ISSN: | 0002-8703 |
| Popis: | Recent studies have indicated that myocardial ischemia could occur and could play an important role in the pathophysiology of patients with hypertrophic cardiomyopathy (HCM). We therefore investigated whether or not dipyridamole--a selective coronary vasodilating agent--could favorably modify myocardial perfusion and the clinical manifestations in 20 patients with HCM (19 nonobstructive and one mildly obstructive) with an average age of 50 years. Oral dipyridamole, 150 mg/day for 2 weeks, prevented reversible perfusion defects initially observed in six patients on baseline exercise thallium-201 (201TI) scintigraphy and significantly increased the 201TI clearance (40 +/- 13% to 44 +/- 12%), while one patient developed new reversible perfusion defects. There were significant increases in echocardiographic fractional shortening and treadmill exercise time and reductions in cardiac size and supraventricular arrhythmias with dipyridamole therapy. These observations suggest that coronary vasodilation with dipyridamole may improve myocardial perfusion and cardiac function in patients with HCM. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|